Indian Court Considers Cipla Challenge To Roche Tarceva Patent
This article was originally published in PharmAsia News
Executive Summary
The Delhi high court is considering a Roche Scientific injunction seeking to halt Cipla's marketing of a generic version of Roche's Tarceva (erlotinib hydrochloride) drug for treating lung cancer. Genentech and OSI Pharmaceuticals, co-developers of the drug, issued a global license to Roche, which obtained the India patent. Besides Cipla, Lawyers Collective, a non-government organization based in Mumbai, was considered another candidate to challenge the Indian patent. Roche India's managing director said marketing a generic would infringe the company's patent. (Click here for more